The invention relates to a novel process for the manufacture of Carvedilol of high HPLC purity (>99.5 %) having individual impurity less than 0.1 %. The product is isolated from reaction mass as a salt with suitable organic acids which on further purification is converted into the free base i.e., Carvedilol.